| Biological Sciences | Lifetime | 93 | BE 2 | 99.99 |
| Biological Sciences | 2021-2025 | 24 | BE 1 | 99.97 |
| Medical and Health Sciences | 2021-2025 | 407 | BE 7 | 99.91 |
| Genetics | Lifetime | 4 | BE 1 | 99.98 |
| Epidemiology | Lifetime | 166 | BE 3 | 99.79 |
| Surgery | Lifetime | 844 | BE 12 | 99.20 |
| Immunology | Lifetime | 374 | BE 7 | 99.06 |
| Gastroenterology | Lifetime | 187 | BE 4 | 97.57 |
| Medical Genetics | Lifetime | 908 | BE 6 | 88.29 |
| Hepatology | Lifetime | 779 | BE 10 | 84.98 |
| Genetics | 2021-2025 | 7 | BE 1 | 99.93 |
| Epidemiology | 2021-2025 | 73 | BE 3 | 99.57 |
| Surgery | 2021-2025 | 231 | BE 7 | 98.57 |
| Immunology | 2021-2025 | 237 | BE 3 | 94.42 |
| Oncology | 2021-2025 | 671 | BE 7 | 89.94 |
| Gastroenterology | 2021-2025 | 153 | BE 7 | 86.21 |
| Medical Genetics | 2021-2025 | 306 | BE 4 | 80.90 |
| Inflammatory Bowel Disease | Lifetime | 2 | BE 1 | 99.99 |
| Microscopic Colitis | Lifetime | 2 | BE 1 | 99.98 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 6 | BE 1 | 99.94 |
| Autoimmune and Inflammatory Disorders | Lifetime | 4 | BE 1 | 99.93 |
| Biosimilars and Bioanalytical Methods | Lifetime | 6 | BE 1 | 99.67 |
| Helicobacter pylori-related gastroenterology studies | Lifetime | 26 | BE 2 | 99.77 |
| Eosinophilic Esophagitis | Lifetime | 24 | BE 2 | 99.78 |
| Celiac Disease Research and Management | Lifetime | 13 | BE 1 | 99.54 |
| Diagnosis and treatment of tuberculosis | Lifetime | 34 | BE 1 | 99.35 |
| Gut microbiota and health | Lifetime | 159 | BE 6 | 99.36 |
| Mycobacterium research and diagnosis | Lifetime | 140 | BE 2 | 99.02 |
| Pregnancy and Medication Impact | Lifetime | 67 | BE 1 | 98.86 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 96 | BE 1 | 99.18 |
| Liver Diseases and Immunity | Lifetime | 77 | BE 2 | 99.08 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 307 | BE 2 | 99.09 |
| Diverticular Disease and Complications | Lifetime | 161 | BE 3 | 98.38 |
| Systemic Lupus Erythematosus Research | Lifetime | 408 | BE 2 | 98.70 |
| Tuberculosis Research and Epidemiology | Lifetime | 470 | BE 8 | 98.31 |
| Pharmaceutical studies and practices | Lifetime | 293 | BE 5 | 97.57 |
| Clostridium difficile and Clostridium perfringens research | Lifetime | 485 | BE 15 | 96.66 |
| IL-33, ST2, and ILC Pathways | Lifetime | 433 | BE 7 | 96.07 |
| Gastrointestinal motility and disorders | Lifetime | 686 | BE 22 | 95.67 |
| Inflammation biomarkers and pathways | Lifetime | 217 | BE 3 | 88.68 |
| Whipple's Disease and Interleukins | Lifetime | 279 | BE 7 | 78.29 |
| Hidradenitis Suppurativa and Treatments | Lifetime | 585 | BE 6 | 75.86 |
| Inflammatory Bowel Disease | 2021-2025 | 6 | BE 1 | 99.92 |
| Helicobacter pylori-related gastroenterology studies | 2021-2025 | 6 | BE 2 | 99.57 |
| Microscopic Colitis | 2021-2025 | 6 | BE 1 | 99.90 |
| Eosinophilic Esophagitis | 2021-2025 | 11 | BE 1 | 99.49 |
| Autoimmune and Inflammatory Disorders | 2021-2025 | 12 | BE 1 | 98.93 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 31 | BE 4 | 97.68 |
| Gut microbiota and health | 2021-2025 | 316 | BE 9 | 97.54 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 81 | BE 3 | 97.48 |
| Liver Diseases and Immunity | 2021-2025 | 58 | BE 1 | 97.73 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 234 | BE 2 | 97.30 |
| Diagnosis and treatment of tuberculosis | 2021-2025 | 45 | BE 1 | 94.35 |
| Celiac Disease Research and Management | 2021-2025 | 50 | BE 1 | 94.86 |
| Immune Cell Function and Interaction | 2021-2025 | 634 | BE 2 | 93.28 |
| Diverticular Disease and Complications | 2021-2025 | 109 | BE 1 | 93.03 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 372 | BE 6 | 94.88 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 486 | BE 3 | 94.23 |
| Pharmacological Effects of Natural Compounds | 2021-2025 | 308 | BE 2 | 88.87 |
| Pregnancy and Medication Impact | 2021-2025 | 224 | BE 2 | 89.83 |
| Pharmaceutical studies and practices | 2021-2025 | 336 | BE 12 | 85.86 |
| Gastrointestinal Tumor Research and Treatment | 2021-2025 | 859 | BE 5 | 82.73 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 549 | BE 12 | 81.25 |
| Clostridium difficile and Clostridium perfringens research | 2021-2025 | 749 | BE 10 | 81.27 |
| Gastrointestinal motility and disorders | 2021-2025 | 658 | BE 24 | 81.70 |
| Digestive system and related health | 2021-2025 | 279 | BE 6 | 77.81 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 734 | BE 3 | 70.52 |
| Hidradenitis Suppurativa and Treatments | 2021-2025 | 367 | BE 5 | 69.23 |
| Inflammation biomarkers and pathways | 2021-2025 | 203 | BE 2 | 60.91 |
| Veterinary medicine and infectious diseases | 2021-2025 | 698 | BE 10 | 47.16 |
| Dermatological and COVID-19 studies | 2021-2025 | 848 | BE 8 | 47.59 |
| Medical and Biological Ozone Research | 2021-2025 | 881 | BE 7 | 31.23 |
